Successful correction of metabolic acidosis is difficult to achieve in chronic kidney disease.

Autor:	Caravaca-Fontán F; Servicio de Nefrología, Hospital Universitario de Badajoz, Badajoz, España. Electronic address: fcaravacaf@gmail.com., Díaz-Campillejo R; Servicio de Nefrología, Hospital Universitario de Badajoz, Badajoz, España., Valladares J; Servicio de Nefrología, Hospital Universitario de Badajoz, Badajoz, España., López Arnaldo C; Servicio de Nefrología, Hospital Universitario de Badajoz, Badajoz, España., Barroso S; Servicio de Nefrología, Hospital Universitario de Badajoz, Badajoz, España., Luna E; Servicio de Nefrología, Hospital Universitario de Badajoz, Badajoz, España., Caravaca F; Servicio de Nefrología, Hospital Universitario de Badajoz, Badajoz, España.
Jazyk:	English; Spanish; Castilian
Zdroj:	Nefrologia [Nefrologia (Engl Ed)] 2020 May - Jun; Vol. 40 (3), pp. 328-335. Date of Electronic Publication: 2019 Dec 18.
DOI:	10.1016/j.nefro.2019.09.006
Abstrakt:	Introduction: Metabolic acidosis (MA) is a common complication of chronic kidney disease (CKD) and is associated with numerous adverse effects, which is why its correction is highly recommended. Oral sodium bicarbonate is the current treatment of choice. Objectives: To describe the prevalence of MA in advanced CKD patients and to determine the clinical and biochemical characteristics associated with its successful correction. Material and Methods: Retrospective, observational cohort study in adult patients with CKD stage 4-5. The inclusion criteria were: not being treated with alkali therapy at the time of inclusion, and to have at least three consecutive glomerular filtration rate (GFR) measurements and biochemical parameters during a minimum follow-up period of 3 months. Incident patients with serum bicarbonate<22 mEq/l were included in the follow-up study and treated with oral sodium bicarbonate. Correction was considered successful when more than half of the samples and the mean bicarbonate levels during individual follow-up were≥22 mEq/l. Results: The study group consisted of 969 patients (age 65±14 years, 507 males) with a mean GFR of 14.8±4.5ml/min/1.73 m 2 . At baseline, 530 patients (55%) had serum bicarbonate<22mEq/l. They were treated with sodium bicarbonate and followed for 15 months. Satisfactory correction of MA was only achieved in 133 patients (25%). By multivariate logistic regression analysis, the main characteristics of patients with adequate control of MA were: age (OR=1.03; 95% CI 1.01 - 1.05), baseline GFR (OR=1.07; 1.02 - 1.12), and treatment with proton-pump inhibitors (OR=1.61; 95% CI 1.06 - 2.44). Patients who achieved successful correction of MA showed slower CKD progression (-1.67±3.71 vs -4.36±4.56ml/min/1.73 m 2 /year, P<.0001), and lower average serum potassium concentration (5.1±0.5 vs 5.3±0.5, P<.0001) than those who did not. However, there were no differences in the hospitalisation or mortality rate. Conclusion: MA is a common complication of advanced CKD but difficult to manage with current therapies. Due to the significant potential benefit of controlling MA, new, more effective therapies should be further researched. (Copyright © 2019 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu